相关实验视频
Updated: Jul 1, 2025

16:11
Implantation of the Syncardia Total Artificial Heart
Published on: July 18, 2014
35.3K
连续的家庭特里普林素输液增加了握力,减少了风 - - 一项前性随机交叉研究
Ryma Terbah1,2, Adam G Testro1,2, Rudolf Hoermann2
1Victorian Liver Transplant Unit, Austin Health, Melbourne, Victoria, Australia.
Hepatology (Baltimore, Md.)
|March 5, 2024
概括
连续输注特里普林素 (CTI) 显著改善了手握强度,并减少了无补偿性肝硬化患者的瘤体积. 这种治疗也提高了生活质量,为管理这种疾病提供了有前途的选择.
科学领域:
- 肝病学 肝病学是一种肝病学.
- 胃肠病学 胃肠病学
- 临床试验 临床试验
背景情况:
- 脱补偿性肝硬化与门性高血压与和肉类有关.
- 观察性研究表明,连续注射特里普林素 (CTI) 可能有利于这些并发症.
研究的目的:
- 为了评估家庭CTI在肝硬化,,和肉症患者的疗效.
主要方法:
- 一个单中心的前性交叉研究随机分配了30名患者进行12周的CTI或观察,随后进行了交叉.
- 同一主要结局包括手握强度和体体积的变化.
主要成果:
- CTI显著增加了手握强度 (3.09公斤增加) 和降低了体积 (11.39L减少).
- 患有CTI的患者经历了较少的宫发作,改善了功能,生活质量得分更高.
- 没有报告心脏事件或肺水;发生了7个轻微的线路相关并发症.
结论:
- 门诊性CTI显著提高肌肉力量,减少瘤的负担,并提高了选择性肝硬化患者的生活质量.
- 这些发现支持CTI作为一种可行的治疗失补偿性肝硬化与和肉类.
相关概念视频
Heart Failure Drugs: Diuretics
375
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
375
Heart Failure Drugs: Inotropic Agents
586
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
586
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
181
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
181
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
165
Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
165
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
429
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
429
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
166
Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
166

